IN THE NEWS

Eiger to Present at Jefferies Virtual Healthcare Conference 2020

May 26th, 2020|

Eiger to Present at Jefferies Virtual Healthcare Conference 2020 PALO ALTO, Calif. – May 26, 2020 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies Virtual Healthcare Conference on June 4, 2020 from 9:30-9:55 PM ET. A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab.  A [...]

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies

May 19th, 2020|

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies PALO ALTO, Calif. May 19, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for accelerated review of ZokinvyTM (lonafarnib) for treatment of Progeria and Progeroid Laminopathies.  The FDA granted Priority Review with a [...]

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

May 7th, 2020|

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update PALO ALTO, Calif. May 7, 2020 — Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a business update. “We achieved key milestones this quarter across programs, including Eiger’s first NDA and MAA submissions.  Lonafarnib would be the first approved treatment for patients with Progeria and Progeroid Laminopathies,” [...]